COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature

Eleonora Virgilio, Giacomo Tondo, Claudia Montabone, Cristoforo Comi

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review

Abstract

Myasthenia gravis (MG) is a rare autoimmune disease that is potentially threatening for patient life. Auto-antibodies targeting structures of the neuromuscular junction, particularly the acetylcholine receptor (AchR), are often found in the serum of MG patients. New-onset MG after SARS-CoV-2 vaccination has rarely been reported since the introduction of vaccination. Infections and COVID-19 infection have also been reported as possible triggers for a myasthenic crisis. We report a case of new-onset MG after receiving the mRNA COVID-19 vaccination. The patient was a 73-year-old male initially presenting with ocular symptoms and a rapid generalization. We also performed a literature revision of 26 described cases of MG after SARS-CoV-2 immunization. The patients were a majority of males with generalized late-onset MG occurring after the first dose of vaccine, similar to our patient. Only our patient showed a thymoma. Thymic mass and the positivity of AchR antibodies suggest that vaccination might have triggered a subclinical pre-existing MG with symptoms flaring. Clinicians should be aware of possible new-onset MG after COVID-19 vaccination, particularly in at-risk patients. Even though COVID-19 vaccination should be recommended in MG patients, particularly in well-compensated patients. However, more studies need to be performed in the future.

Lingua originaleInglese
Numero di articolo467
RivistaInternational Journal of Environmental Research and Public Health
Volume20
Numero di pubblicazione1
DOI
Stato di pubblicazionePubblicato - gen 2023

Fingerprint

Entra nei temi di ricerca di 'COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature'. Insieme formano una fingerprint unica.

Cita questo